Short Interest in IN8bio, Inc. (NASDAQ:INAB) Drops By 6.6%

IN8bio, Inc. (NASDAQ:INAB) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 176,500 shares, a decrease of 6.6% from the September 15th total of 188,900 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average daily volume of 259,500 shares, the days-to-cover ratio is currently 0.7 days.

IN8bio Stock Down 2.2 %

Shares of INAB traded down $0.01 during trading hours on Wednesday, reaching $0.23. The stock had a trading volume of 247,023 shares, compared to its average volume of 334,044. The company has a market capitalization of $10.10 million, a price-to-earnings ratio of -0.26 and a beta of -0.05. The firm has a 50-day simple moving average of $0.41 and a 200 day simple moving average of $0.79. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.04. IN8bio has a 12 month low of $0.22 and a 12 month high of $2.48.

IN8bio (NASDAQ:INAB) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). Equities research analysts predict that IN8bio will post -0.65 earnings per share for the current fiscal year.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.